| | Study ID | Region | RVO type | No. of patients (T/C) | No. of eyes (T/C) | Length of follow-up(months) | Age | Gender (M/F) | Intervention | Duration of RVO (T/C) | The course of treatment (weeks) | Outcome | | T | C | T | C | T | C |
| | Su et al. 2021 [19] | China | CRVO | 30/30 | 30/30 | 6 | 58.76 ± 14.52 | 54.2 ± 9.1 | 13/17 | 16/14 | 1.25 mg IVB + CHM | 1.25 mg IVB | 3.01 ± 3.23/2.85 ± 2.78 (months) | 12 | a, b, c, d | | Wang et al. 2020 [23] | China | BRVO | 46/46 | 46/46 | 6 | 53.73 ± 7.15 | 51.45 ± 6.43 | 24/22 | 20/26 | 0.5 mg IVR + CHM | 0.5 mg IVR | 1.78 ± 0.44/1.89 ± 0.35 (months) | 12 | a, b, c, d | | Hao 2019 [21] | China | BRVO | 50/50 | 50/50 | 6 | 57.09 ± 14.35 | 58.83 ± 12.43 | 27/23 | 26/24 | 0.5 mg IVC + CHM | 0.5 mg IVC | 27.2 ± 12.4/28.6 ± 12.2 (days) | 24 | a, b, c, d | | Wei et al. 2020 [26] | China | RVO | 75/75 | 75/75 | 12 | 45.2 ± 3.3 | 45.3 ± 3.4 | 40/35 | 39/36 | Anti-VEGF + CHM | Anti-VEGF | 0.8 ± 0.2/0.8 ± 0.1 (months) | 4 | a, b, d | | Sha and Duan 2018 [25] | China | RVO | 21/21 | 21/21 | 6 | 40∼75 | 40∼75 | 12/9 | 10/11 | 0.5 mg IVR + CHM | 0.5 mg IVR | 1∼3 (months) | 3∼6 | b | | Wu et al. 2020 [26] | China | RVO | 32/25 | 32/25 | 6 | 54.13 ± 11.542 | 60.84 ± 8.971 | 19/13 | 10/15 | Anti-VEGF + CHM | Anti-VEGF | NA | 12 | a, b, c | | Tao et al. 2017 [18] | China | CRVO | 30/30 | 30/30 | 6 | 55.17 ± 10.66 | 34/26 | 0.5 mg IVR + CHM | 0.5 mg IVR | 57.3 ± 16.9 (days) | 12 | b | | Yan 2017 [20] | China | BRVO | 32/30 | 32/30 | 6 | 56.0 ± 0.91 | 53.9 ± 1.10 | 18/14 | 20/10 | 0.5 mg IVR + CHM | 0.5 mg IVR | 2.16 ± 0.37/1.89 ± 0.18 (months) | 4 | a, b, c | | Ming. 2019 [22] | China | BRVO | 30/30 | 30/30 | 6 | 54.96 ± 13.70 | 52.92 ± 19.06 | 11/16 | 10/15 | 0.5 mg IVC + CHM | 0.5 mg IVC | NA | 12 | a, b, c | | Lu and Wu 2018 [24] | China | RVO | 30/30 | 30/30 | 6 | 61.80 ± 7.26 | 61.17 ± 7.47 | 15/15 | 14/16 | 0.5 mg IVR + CHM | 0.5 mg IVR | 1.70 ± 0.63/1.68 ± 0.69 | 24 | a, b, d |
|
|
Note: T: treatment group, C: control group, NA: not available, M/F: male/female, CHM: Chinese herbal medicine, anti-VEGF: antivascular endothelial growth factor, BCVA: best corrected visual acuity, CMT: central macular thickness, IVB: intravitreal bevacizumab, IVR: intravitreal ranibizumab, and IVC: intravitreal conbercept. Outcomes: a: BCVA, b: CMT, c: number of injections, and d: total clinical efficacy.
|
